small molecule

FANAPT

ILOPERIDONE

Loss of exclusivityDecember 2031latest FDA-listed patent expiry

CompanyVanda Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	FANAPT
Active ingredient	ILOPERIDONE
Strength	2MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2009
Marketing status	RX

Listed patents

Patent	Expires	Type
9074254	December 2031	use U-1674
9074256	February 2031	use U-1674
9072742	January 2031	use U-1674
9074255	December 2030	use U-1674
8999638	October 2030	use U-1674
12606869	September 2030	use U-4505
8652776	August 2030	use U-1685
10563259	July 2030	use U-4563
9157121	April 2030	use U-1674
10570453	March 2028	use U-4563
8586610	November 2027	use U-1625

Regulatory exclusivity

Code	Expires
I-939	April 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Vanda Pharmaceuticals